BOM:543828 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BOM:543828 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Sudarshan Pharma Industries Ltd BOM:543828
Sudarshan Pharma Industries BOM:543828 -5.00% 69 LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus rates BOM:543828 with a GF Score™ of 69/100 and a GF Value™ of ₹6.52 (Significantly Overvalued). The stock has 14 warning signs investors should review.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sudarshan Pharma Industries's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.05.
Sudarshan Pharma Industries's long-term debt to total assets ratio increased from Mar. 2025 (0.03) to Mar. 2026 (0.05). It may suggest that Sudarshan Pharma Industries is progressively becoming more dependent on debt to grow their business.
Sudarshan Pharma Industries (BOM:543828) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
The historical data trend for Sudarshan Pharma Industries's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| Sudarshan Pharma Industries Annual Data | |||||||||||||||||||||
| Trend | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | Mar24 | Mar25 | Mar26 | |||||||||||
| LT-Debt-to-Total-Asset | Get a 7-Day Free Trial |
|
|
0.04 | 0.06 | 0.04 | 0.03 | 0.05 | |||||||||||||
| Sudarshan Pharma Industries Quarterly Data | |||||||||||||||||||
| Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Sep21 | Mar22 | Sep22 | Mar23 | Sep23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | Jun25 | Sep25 | Dec25 | Mar26 | |
| LT-Debt-to-Total-Asset | Get a 7-Day Free Trial |
|
|
|
|
|
|
|
|
|
|
|
0.03 | 0.00 | 0.07 | 0.00 | 0.05 | ||
Sudarshan Pharma Industries's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
| LT Debt to Total Assets (A: Mar. 2026 ) | = | Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 ) | / | Total Assets (A: Mar. 2026 ) |
| = | 286.283 | / | 6417.491 | |
| = | 0.04 |
Sudarshan Pharma Industries's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as
| LT Debt to Total Assets (Q: Mar. 2026 ) | = | Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 ) | / | Total Assets (Q: Mar. 2026 ) |
| = | 286.283 | / | 6417.491 | |
| = | 0.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Based on GuruFocus' analysis, Sudarshan Pharma Industries stock appears to be overvalued. The current stock price of ₹32.49 is trading 398.3% above its estimated GF Value™ of ₹6.52. GuruFocus considers Sudarshan Pharma Industries to be Significantly Overvalued.
Key valuation signals for BOM:543828:
No single metric tells the full story. See the BOM:543828 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.